Risk stratification for worsening renal function and renal decline in heart failure patients with reduced ejection fraction after sacubitril/valsartan treatment

Background: In the real-world setting, data regarding renal decline following sacubitril/valsartan treatment are lack-ing. This study aimed to develop a scoring system to predict renal outcome in sacubitril/valsartan-treated patients.Methods: Between 2017 and 2018, a total of 1505 heart failure patients with reduced ejection fraction (HFrEF) un-dergoing sacubitril/valsartan treatment were consecutively enrolled from 10 hospitals to serve as the derivation co-hort. Another 1620 HFrEF patients receiving sacubitril/valsartan were included as the validation cohort. Worsening renal function (WRF) was defined as a serum creatinine increase of >0.3 mg/dL and/or >25 % at 8 months of sacu-bitril/valsartan treatment. The derivation cohort was used to identify independent predictive factors for WRF through multivariate analysis, which were then used to develop the risk score system.Results: Among the 3125 HFrEF patients, 689 (22.0 %) patients had WRF at 8 months following sacubitril/valsartan treatment. In the derivation cohort, six prognostic factors (age, functional class, history of peripheral arterial disease, diabetes mellitus, gout or hyperuricemia, and serum albumin level) were independently associated with WRF, and were combined into a risk predicting score. This score showed accurate discrimination in the derivation and valida-tion cohorts (Harrell's concordance indexes 0.74 and 0.71, 95 % confidence intervals 0.71-0.78 and 0.69-0.74, re-spectively). Patients with a higher risk score experienced a more rapid decline in renal function, poorer clinical outcomes, and a higher rate of discontinuation of sacubitril/valsartan treatment.Conclusions: This study developed a score for WRF after sacubitril/valsartan treatment, which may assist clinicians with risk stratification and therapeutic decision-making.(c) 2023 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.